Vertical: CNMBase Year: 2025
Market Size (2025)
$124.49M
Projected (2032)
$175.44M
CAGR (2022–2032)
5.0%
Key Players
10+
Market Overview
The Global Amprolium Market was valued at USD 124.49 Million in 2025 and is projected to reach USD 175.45 Million by 2032, expanding at a CAGR of 5.02% over 2026–2032. The market grew from USD 107.44 Million in 2022 to USD 118.53 Million in 2024, and the forecast period adds an absolute increment of USD 50.96 Million between 2025 and 2032. Growth is steady rather than rapid, reflecting the position of amprolium as a mature, off-patent anticoccidial whose demand tracks the volume of commercial poultry and calf production more closely than it tracks product innovation.
Amprolium is a thiamine-analogue anticoccidial used to prevent and treat coccidiosis caused by Eimeria species, chiefly in chickens and turkeys and secondarily in calves and other ruminants. It is supplied as feed premixes and Type A medicated articles for continuous in-feed prevention, and as water-soluble powders and oral solutions for therapeutic use in drinking water. Its wide safety margin, its approval for use in laying hens in several jurisdictions, and its classification outside the medically important antimicrobials in the United States support its continued use in both conventional and reduced-antibiotic production systems.
Key Findings
By Livestock: Broilers are the largest segment with USD 93.37 Million in 2025, a 75.00% share. Layers & Breeders are the fastest-growing segment at a CAGR of 7.39%, rising from USD 12.45 Million in 2025 to USD 20.50 Million in 2032.
By Physical Form: Premix leads with USD 99.59 Million in 2025 (80.00% share) and is also the faster-growing form at a CAGR of 5.18%, against 4.36% for Others.
By Region: Asia Pacific is the leading region with USD 52.29 Million in 2025 (42.00% share). Middle East & Africa is the fastest-growing region at a CAGR of 6.81%.
By Country: China is the leading country market with USD 20.91 Million in 2025. UAE is the fastest-growing country at a CAGR of 7.69%, while India combines scale (USD 13.59 Million in 2025) with an above-average CAGR of 6.55%.
Segmentation Summary
The market is analysed by livestock (Broilers, Layers & Breeders, Cattle & Others), by physical form (Premix, Others) and by region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), with country-level estimates within each region. Broilers account for 75.00% of 2025 value because broiler production is the largest consumer of in-feed anticoccidials, while Cattle & Others hold 15.00% and Layers & Breeders 10.00%. Premix accounts for 80.00% of value, reflecting the dominance of continuous in-feed prevention in integrated poultry operations; the Others form, which comprises water-soluble powders, oral solutions and other non-premix presentations, accounts for 20.00%.
Competitive Landscape Summary
The competitive field is led by a small number of companies with regulatory approvals for branded amprolium premixes and oral products, surrounded by a wider group of generic manufacturers and API suppliers. Huvepharma holds the AMPROL and CORID franchises and is the sole sponsor of amprolium Type A medicated articles in the United States. Phibro Animal Health supplies amprolium mainly as an active pharmaceutical ingredient and strengthened its anticoccidial position through the acquisition of the Zoetis medicated feed additive portfolio, completed in October 2024. Bimeda and Aurora Pharmaceutical compete in North American oral generics, while Virbac, Interchemie, Dopharma, Kepro and S P Veterinaria serve poultry and livestock producers in Asia, Europe, Africa and the Middle East with water-soluble and oral formulations. Chinese API producers such as Jiangsu Lingyun Pharmaceutical supply amprolium hydrochloride to formulators worldwide.
Challenges and Opportunities
The principal challenges are the growing use of live coccidiosis vaccines, the retreat of some large US integrators from No-Antibiotics-Ever programmes (which restores the use of ionophores in place of chemical anticoccidials), the development of reduced Eimeria sensitivity after prolonged use, and tight residue limits in some importing markets. Opportunities arise from expanding poultry production in Asia Pacific, Latin America and Africa, the need for chemical anticoccidials in rotation and shuttle programmes alongside ionophores and vaccines, the authorisation of amprolium hydrochloride as a coccidiostat feed additive in the European Union in 2021, and demand for drinking-water treatments in layer, breeder and calf operations.
Future Outlook
The market is expected to expand every year of the forecast period, from USD 130.75 Million in 2026 to USD 175.45 Million in 2032. Asia Pacific will contribute the largest absolute gain (USD 23.13 Million between 2025 and 2032), while Middle East & Africa and Layers & Breeders will post the highest growth rates within their respective segmentations. Competitive differentiation is expected to rest on regulatory coverage across jurisdictions, reliable API supply, integration of amprolium into coccidiosis-control programmes with vaccines and other anticoccidials, and technical support to integrators and feed mills.
The Amprolium Market market is projected to grow at a CAGR of 5.0% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Amprolium (1-[(4-amino-2-propyl-5-pyrimidinyl)methyl]-2-methylpyridinium chloride, used as the hydrochloride salt) is a synthetic quaternary pyrimidine derivative and structural analogue of thiamine (vitamin B1). It competitively inhibits thiamine uptake by developing Eimeria parasites, acting principally on first-generation schizonts, and is most active against Eimeria tenella and Eimeria acervulina. Because high dietary thiamine antagonises its activity, the vitamin B1 content of medicated feed is controlled. Amprolium was introduced to the market in 1960 and is now produced and formulated by multiple manufacturers worldwide.
For the purposes of this study, the market includes the value of amprolium-based veterinary products sold for coccidiosis prevention and treatment, comprising:
Amprolium premixes and Type A medicated articles incorporated into compound feed, including approved combinations in which amprolium is the anticoccidial component
Water-soluble powders, oral solutions and other non-premix presentations administered through drinking water or orally
Products for broiler chickens, laying hens and breeders, cattle and calves, and other species such as turkeys, sheep, goats and game birds
The study excludes other anticoccidial actives (ionophores such as monensin, salinomycin and narasin, and chemicals such as toltrazuril, diclazuril, nicarbazin and decoquinate) when sold without amprolium, live and attenuated coccidiosis vaccines, thiamine and other vitamin supplements, phytogenic and probiotic coccidiosis-support additives, and human pharmaceutical uses.
Scope of the Study
The study quantifies the market in USD Million for the historic years 2022–2024, the base year 2025 and the forecast years 2026–2032, with compound annual growth rates stated for 2026–2032. The scope covers the following segmentations:
By Livestock: Broilers; Layers & Breeders; Cattle & Others
By Physical Form: Premix; Others
By Region: North America (U.S., Canada, Mexico); Europe (Germany, U.K., France, Italy, Spain, Rest of Europe); Asia Pacific (China, India, Japan, Rest of Asia Pacific); Latin America (Brazil, Argentina, Rest of Latin America); Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of MEA)
Research Objectives
To estimate the size of the global amprolium market for 2022–2025 and forecast it for 2026–2032 in USD Million
To analyse demand by livestock category, distinguishing broiler, layer and breeder, and cattle and other species applications
To assess the relative position and growth of premix and non-premix (water-soluble and oral) product forms
To quantify regional and country-level demand and identify the fastest-growing geographies for amprolium
To evaluate the drivers, restraints, opportunities and trends shaping amprolium use, including antibiotic-reduction programmes, vaccination and anticoccidial resistance
To review the regulatory framework for amprolium in major markets, including approvals, feed additive authorisations and residue limits
To identify the leading manufacturers and suppliers and assess their competitive positioning and recent strategic developments
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured process combining secondary research, primary validation and quantitative modelling. The process began with the definition of the market and its segmentation, followed by the collection of data on livestock populations, poultry and cattle production, anticoccidial usage patterns, product registrations and company activity. Market estimates were then built through complementary top-down and bottom-up approaches, validated with industry participants and triangulated to arrive at final values for each segment, region and country. The forecast was developed by applying growth assumptions linked to measurable demand indicators and qualitative assessments of regulatory and technological change.
Secondary Research
Secondary research established the baseline understanding of the market and supplied the inputs for sizing. The principal source types were:
Government and regulatory bodies: the U.S. Food and Drug Administration Center for Veterinary Medicine (approved animal drug lists and the Code of Federal Regulations), the European Medicines Agency and the European Commission (MRL and feed additive regulations), the UK Veterinary Medicines Directorate, the Canadian Food Inspection Agency, China's Ministry of Agriculture and Rural Affairs, Japan's Ministry of Health, Labour and Welfare, India's FSSAI and Department of Animal Husbandry and Dairying, and Brazil's Ministry of Agriculture.
Production and trade statistics: USDA Foreign Agricultural Service livestock and poultry reports, FAO statistics and national livestock census and animal husbandry publications.
Industry associations: national and regional poultry, feed and animal health associations, which publish production data and policy positions on antimicrobial use and coccidiosis control.
Company filings and disclosures: annual reports, investor presentations, product labels and registration records of animal health companies and API manufacturers.
Trade and scientific journals: poultry, feed and veterinary publications and peer-reviewed literature on coccidiosis economics, anticoccidial efficacy and resistance.
Paid databases: company, trade and pharmaceutical ingredient databases used to identify producers, product registrations and trade flows.
Primary Research
Primary research was used to validate secondary findings, refine assumptions and obtain qualitative insight into market behaviour. Discussions were held with participants on both the supply and demand sides of the value chain.
Supply side: executives and product managers at animal health companies, API manufacturers, premix and feed additive producers, and distributors of veterinary products.
Demand side: poultry and cattle veterinarians, nutritionists at integrated poultry companies and feed mills, layer and breeder farm managers, and veterinary pharmacy and farm supply buyers.
Objectives: to confirm product usage patterns and dosing practices, understand rotation and shuttle programmes, gauge the influence of vaccines and antibiotic-reduction policies, verify pricing and channel structures, and test the reasonableness of segment and regional estimates.
Market Size Estimation
Two independent approaches were used to estimate market size.
Top-down approach: the overall anticoccidial and medicated feed additive market was used as the starting point, and the share attributable to amprolium was derived from product registrations, usage patterns and company revenue information. This total was then allocated to livestock categories, product forms and regions using production data and usage intensities.
Bottom-up approach: demand was built from the number of birds and animals treated, typical inclusion rates and treatment durations for premix and drinking-water products, and average realised prices by region. Country estimates were aggregated into regional and global totals.
Data triangulation: the results of both approaches were compared with supply-side information and primary research inputs. Differences were reconciled by adjusting the underlying assumptions until the estimates converged within an acceptable range.
Forecasting Methodology
The forecast was developed by projecting the base-year estimates for each segment and country using growth assumptions derived from the following factors:
Projected growth in broiler, layer and cattle production by country, based on official and international production outlooks
Changes in anticoccidial programme design, including the share of flocks managed under vaccination, rotation and antibiotic-reduction schemes
Regulatory developments affecting approvals, feed additive authorisations, residue limits and medicated feed rules
Price trends for amprolium API and finished products, including the effect of generic competition
Macroeconomic indicators such as income growth, protein consumption and feed costs
Segment-level forecasts were reconciled with regional and global totals so that each segmentation sums to the overall market in every year.
Base Year, Forecast Period and Currency
Assumptions and Limitations
Market values are expressed at manufacturer selling-price level and exclude distributor and retail margins, feed costs and taxes.
The regulatory status of amprolium in each major market is assumed to remain broadly unchanged during the forecast period, apart from developments already announced.
No major disruption to poultry production, such as an extreme avian influenza season or trade embargo, is assumed beyond normal cyclical variation.
Exchange rates are held constant, so values do not reflect future currency movements.
Usage of amprolium in smallholder and backyard production is estimated with lower precision than usage in integrated commercial operations because of limited reporting.
Several market participants are privately held and do not disclose product-level revenue, which limits the precision of supply-side cross-checks.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The amprolium market is moderately consolidated. Branded premix and Type A medicated article supply is concentrated among a small number of companies that hold the necessary regulatory approvals and manufacturing assets, while the water-soluble and oral segment is more fragmented, with numerous generic manufacturers supplying national and export markets. In the United States, Huvepharma is the sole sponsor of amprolium Type A medicated articles under 21 CFR 558.55, while oral amprolium solutions and powders are approved for four sponsors: Huvepharma, Bimeda, Aurora Pharmaceutical and Phibro Animal Health. In Europe, amprolium drinking-water products are authorised for several manufacturers, including Huvepharma, S P Veterinaria, Dopharma, Kepro, V.M.D. and Laboratoires Biové, and Huvepharma holds the EU feed additive authorisation for amprolium hydrochloride.
Competition is based on regulatory coverage, price, supply reliability, product quality and technical service to integrators and veterinarians, rather than on innovation in the molecule itself. Because amprolium is one component of broader coccidiosis-control programmes, companies with wide anticoccidial portfolios, including ionophores, other chemicals and vaccines, are able to offer integrated programmes and strengthen customer relationships. Supply of amprolium hydrochloride API from Chinese manufacturers, such as Jiangsu Lingyun Pharmaceutical, underpins the generic segment.
Key Player Positioning
Leaders: Huvepharma and Phibro Animal Health. Huvepharma owns the AMPROL and CORID franchises, is vertically integrated in anticoccidial production and holds approvals across North America and Europe. Phibro Animal Health, which reported net sales of USD 1,518.1 million for the fiscal year ended June 2026, supplies amprolium mainly as an active pharmaceutical ingredient and in oral and combination products, and has broadened its anticoccidial portfolio through the acquisition of the Zoetis medicated feed additive business.
Challengers: Bimeda, Virbac and Interchemie. Bimeda supplies FDA-approved generic amprolium solutions and powders, including private-label products for North American distributors, and has expanded in Africa. Virbac, with revenue of EUR 1,464.7 million in 2025, markets amprolium soluble powder in India and has a broad farm animal presence in Asia. Interchemie supplies amprolium water-soluble products through a large distributor network in Africa and the Middle East.
Niche players: Dopharma, Kepro, S P Veterinaria, Aurora Pharmaceutical and Jiangsu Lingyun Pharmaceutical. These companies compete in specific geographies or product forms, such as European drinking-water solutions (Dopharma, Kepro, S P Veterinaria), US generic oral products for poultry and calves (Aurora Pharmaceutical) or API supply (Jiangsu Lingyun Pharmaceutical). Other smaller participants include V.M.D., Laboratoires Biové and Cenavisa in Europe.
Threat of New Entrants: Low
Product approvals for veterinary drugs and feed additives require extensive safety, residue and efficacy data, and the cost and time of registration deter new entrants.
Established suppliers hold long-standing relationships with integrators and feed mills, which value consistent performance and technical support.
Generic oral formulations face lower barriers in some markets, but premix approvals remain concentrated among a few holders.
Bargaining Power of Suppliers: Medium
API production is concentrated among a limited number of manufacturers, many located in China, giving them some pricing power over non-integrated formulators.
Vertically integrated companies reduce their exposure to supplier power by producing their own active ingredient.
Excipients and carriers are commodity inputs with many alternative sources.
Bargaining Power of Buyers: High
Large integrators and feed mill groups purchase in volume and negotiate prices across their whole anticoccidial programme.
Buyers can choose among several anticoccidial classes and vaccines, and switching between products within a rotation programme is routine.
Distributors of generic oral products compete on price, increasing price transparency.
Threat of Substitutes: High
Ionophores such as monensin, salinomycin and narasin are widely used in conventional broiler production and compete directly with amprolium.
Other chemical anticoccidials (toltrazuril, diclazuril, nicarbazin, decoquinate) and live coccidiosis vaccines provide alternative control options.
Phytogenic, probiotic and other gut-health additives are being positioned as supportive alternatives in antibiotic-free programmes.
Competitive Rivalry: Medium
A small number of companies hold branded premix approvals, while competition among generic oral products is more intense.
Competition is based on price, regulatory coverage, supply reliability and technical service rather than product innovation.
Steady market growth moderates rivalry, as suppliers can grow with livestock production without displacing competitors.
Threat of New Entrants: Low; High regulatory and registration barriers; entrenched customer relationships.
Bargaining Power of Suppliers: Medium; Concentrated API production offset by vertical integration.
Bargaining Power of Buyers: High; Large integrators and feed mills with multiple product options.
Threat of Substitutes: High; Ionophores, other chemicals, vaccines and gut-health additives.
Competitive Rivalry: Medium; Concentrated premix supply; price competition in generic oral products.
Market estimates by geography (2032)
InsightAsia Pacific leads with $75.42M by 2032, while Middle East & Africa is projected to grow fastest at a 6.8% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $19.95M | $24.19M | $29.47M | 4.0% | 17% |
| Europe | $16.60M | $20.18M | $24.61M | 4.0% | 14% |
| Asia Pacific | $44.58M | $58.16M | $75.42M | 5.4% | 43% |
| Latin America | $19.16M | $24.87M | $32.15M | 5.3% | 18% |
| Middle East & Africa | $7.15M | $9.93M | $13.80M | 6.8% | 8% |
| Total | $107.44M | $137.33M | $175.44M | 5.0% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$175.44M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Broilers | $130.42M | 4.9% | 74% |
| Cattle & Others | $24.52M | 4.0% | 14% |
| Layers & Breeders | $20.50M | 7.4% | 12% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Amprolium Market covering market dynamics, competitive landscape, and strategic outlook.
The Amprolium Market market is projected to reach $175.44M by 2032, growing at 5.0% CAGR. The Broilers segment holds the largest share.
The Global Amprolium Market is shaped by the scale and structure of global poultry and cattle production, the economic burden of coccidiosis, regulatory policy on antimicrobial use in food animals and the evolution of coccidiosis-control programmes. This chapter assesses the factors that promote or inhibit growth, followed by a discussion of drivers, restraints, opportunities, trends and challenges. The impact scores in the growth factor analysis are analyst assessments, rated on a scale of 1 to 10 for each forecast sub-period, where higher scores indicate a stronger influence on the market.
Expanding Global Poultry Production
Poultry is the fastest-growing source of animal protein worldwide, and its expansion is the most important driver of amprolium demand. The USDA Foreign Agricultural Service estimates global chicken meat production at about 108.0 million tonnes in 2025 and forecasts about 110.7 million tonnes in 2026, led by the United States, China, Brazil and the European Union. Growth is concentrated in integrated broiler systems with high stocking densities, where Eimeria oocysts accumulate in litter and coccidiosis prevention is applied to virtually every flock. Each additional flock placed in such systems creates incremental demand for in-feed anticoccidials or for vaccination combined with chemical support. Rising production in China, India, Brazil, Southeast Asia and Africa, supported by urbanisation, income growth and investment in integrated processing, is therefore expected to sustain volume growth for amprolium premixes and water-soluble products throughout the forecast period. Export-oriented producers in Brazil and China also maintain disciplined disease-control programmes to meet the performance and food safety standards of importing countries, which supports the use of approved anticoccidials with well-characterised residue profiles.
High Economic Burden of Coccidiosis
Coccidiosis remains one of the most costly diseases in commercial poultry. A widely cited study by Blake and colleagues (2020) estimated the global cost of coccidiosis in chickens at approximately GBP 10.4 billion at 2016 prices, equivalent to about GBP 0.16 per chicken produced, through mortality, reduced weight gain, poorer feed conversion and the cost of prophylaxis and treatment. Subclinical infection impairs nutrient absorption and predisposes birds to necrotic enteritis, so the economic loss extends well beyond visible outbreaks. These losses make anticoccidial programmes a standard cost of production rather than a discretionary purchase, and producers continue to rely on proven actives such as amprolium for both prevention and the treatment of clinical outbreaks. In calves, coccidiosis caused by Eimeria bovis and Eimeria zuernii causes diarrhoea and growth retardation, supporting demand for oral amprolium treatments in dairy and beef calf rearing.
Antibiotic-Reduction Policies Favouring Non-Antibacterial Anticoccidials
Policies that restrict the use of antibiotics in food animals have increased the importance of anticoccidials that are not classed as medically important antimicrobials. In the United States, amprolium is not included in the Veterinary Feed Directive drug list and remains available over the counter, and FDA and USDA treat ionophores as antibiotics for labelling purposes, so chemical anticoccidials such as amprolium are among the few in-feed options available to flocks raised without antibiotics. In China, MARA Announcement No. 194 withdrew growth-promoting drug feed additives from 2020 while retaining anticoccidials for use in commercial feed, and in Brazil, Normative Instruction No. 1 of 2020 banned tylosin, lincomycin and tiamulin as performance enhancers without restricting registered anticoccidials. These frameworks leave amprolium as a permitted tool in markets where antibiotic use is being curtailed, and its inclusion in antibiotic-free and reduced-antibiotic programmes, often in combination with vaccination, supports steady demand.
Suitability for Layers, Breeders and Drinking-Water Treatment
Amprolium is one of the few anticoccidials approved for use in laying hens in the United States, where federal regulations set tolerances for amprolium residues in eggs and the approved Type A medicated article carries no withdrawal period when used according to label. This allows its use in replacement pullets, breeders and laying flocks, where many other anticoccidials are restricted. Its availability as water-soluble powders and oral solutions also makes it a first-line therapeutic option for treating clinical outbreaks, as drinking-water administration reaches sick birds that have reduced feed intake. The growth of cage-free and free-range layer housing, in which birds have greater contact with litter and faeces, increases coccidiosis exposure in layer flocks. These factors explain why Layers & Breeders are the fastest-growing livestock segment, with a CAGR of 7.39% over 2026–2032.
Feed Additive Authorisation in the European Union
In November 2021, Commission Implementing Regulation (EU) 2021/2047 authorised amprolium hydrochloride (COXAM, held by Huvepharma NV) as a coccidiostat feed additive for chickens for fattening and chickens reared for laying, valid until December 2031. This gives amprolium a route into compound feed in the European Union alongside its established use as a veterinary medicinal product in drinking water, and creates an opportunity to increase premix penetration in European broiler and pullet production during the forecast period.
Poultry Expansion in Emerging Markets
Poultry production is expanding fastest in Asia, Latin America, the Middle East and Africa, where integrated production is replacing backyard systems and commercial feed milling is growing. India produced about 149 billion eggs in 2024–25 according to the Department of Animal Husbandry and Dairying, and its broiler sector continues to integrate. Gulf states are investing in domestic poultry capacity to improve food security, and African markets are building commercial broiler and layer industries. These markets currently use relatively low levels of vaccination and depend heavily on cost-effective chemical anticoccidials, which positions amprolium for above-average growth; Middle East & Africa records the highest regional CAGR of 6.81%.
Integrated Coccidiosis-Control Programmes
Producers increasingly design coccidiosis control as a programme that combines vaccines, ionophores, chemical anticoccidials and gut-health additives in rotation or shuttle schemes, to manage resistance and protect performance. Amprolium's mode of action differs from that of ionophores and most other chemicals, and it can be used in drinking water to support vaccinated flocks during the vaccine reaction period. Suppliers that provide technical service, sensitivity testing and programme design can expand the role of amprolium within these programmes.
Growing Use of Coccidiosis Vaccines
Live coccidiosis vaccines, administered as sprays or in feed and water at the hatchery or on farm, are increasingly used in broiler breeders, layers and antibiotic-free broiler programmes. Products such as Evalon, which received a positive opinion from the EMA's Committee for Medicinal Products for Veterinary Use in 2016, provide immunity against multiple Eimeria species and reduce reliance on continuous in-feed medication. Organic production systems in several markets may use only vaccines for coccidiosis control. Wider vaccine adoption directly reduces the number of bird-days on in-feed anticoccidials, although amprolium is often retained as a supportive treatment because it allows some parasite development and does not prevent the establishment of vaccine immunity.
Shift Away from No-Antibiotics-Ever Programmes in the United States
After rapid growth in the 2010s, the share of US broilers raised under No-Antibiotics-Ever claims has plateaued, and some large producers have changed their claims to permit ionophores. In July 2023, Tyson Foods moved its branded chicken from a No-Antibiotics-Ever standard to "No Antibiotics Important to Human Medicine", allowing the reintroduction of ionophores. Ionophores are generally preferred in conventional broiler programmes for cost and efficacy reasons, so this shift reduces one of the demand supports for chemical anticoccidials such as amprolium in the largest single country market.
Resistance, Efficacy Limits and Species Safety
Prolonged use of any anticoccidial leads to reduced sensitivity among Eimeria populations, and the European Union authorisation of amprolium hydrochloride as a feed additive requires post-market monitoring of Eimeria resistance. Amprolium is also less active against some economically important species, such as Eimeria maxima, than against Eimeria tenella and Eimeria acervulina, so it is frequently used in combinations or rotations. In ruminants, excessive or prolonged dosing of thiamine analogues can cause polioencephalomalacia, which requires careful adherence to label dosing in cattle and limits indiscriminate use.
Programme-Based Coccidiosis Management
Integrators are moving from single-product prophylaxis to programme-based coccidiosis management, combining vaccination, rotation of anticoccidial classes and monitoring of lesion scores and oocyst counts. This trend favours suppliers with broad anticoccidial portfolios and strong technical support capabilities, and it shapes where and how amprolium is used across the production cycle.
Consolidation of Medicated Feed Additive Portfolios
The medicated feed additive sector is consolidating. Phibro Animal Health completed the acquisition of the Zoetis medicated feed additive portfolio and certain water-soluble products in October 2024, and FDA approvals for several anticoccidial combinations, including the amprolium and ethopabate combination with bacitracin, were transferred from Zoetis to Phibro in 2026. Consolidation concentrates regulatory dossiers and manufacturing assets in companies that specialise in livestock health.
Divergent Regulatory Treatment and Residue Standards
Regulatory treatment of amprolium differs significantly between markets. The European Union lists amprolium for poultry as requiring no MRL, the United States sets tolerances for tissues and eggs, and India sets a tolerance limit of 0.01 mg/kg for edible animal tissues and milk. There is no Codex MRL, and JECFA has not evaluated the substance. In Great Britain, the Food Standards Agency's 2023 safety assessment of the COXAM feed additive could not conclude on consumer safety because of data gaps. These differences complicate global product registration and trade in animal products and are a continuing challenge for suppliers.
Supply Chain Concentration in API Manufacturing
A significant share of amprolium active pharmaceutical ingredient is manufactured in China, and formulators in other regions depend on a limited number of qualified API sources. Episodes of supply disruption, environmental inspections and freight volatility have encouraged animal health companies to invest in vertically integrated supply and dual sourcing, which is shaping procurement strategies across the industry.
The amprolium value chain comprises four principal stages, from chemical inputs to the producer who administers the product to animals.
Raw materials and inputs: amprolium is synthesised from pyrimidine intermediates and 2-picoline (2-methylpyridine) and converted into its hydrochloride salt. Inputs include basic chemicals, solvents and the excipients and carriers used in formulation, such as calcium carbonate, rice hulls or wheat middlings for premixes and soluble carriers for powders. The stage is sensitive to the price and availability of chemical intermediates, much of which originate in China.
Manufacturing: API manufacturers produce amprolium hydrochloride under GMP conditions and supply it to formulators. Animal health companies then manufacture Type A medicated articles and premixes, water-soluble powders and oral solutions, and obtain the product approvals required in each market. Some companies, such as Huvepharma, are vertically integrated from active ingredient to finished product.
Distribution and channels: premixes are sold directly to integrated poultry companies and feed mills or through premix and feed additive distributors, which incorporate them into compound feed. Water-soluble and oral products reach farms through veterinary distributors, veterinary practices, farm supply retailers and online stores. Export-oriented manufacturers in Europe rely on national distributor networks in Africa, the Middle East and Asia.
End users: integrated broiler companies, layer and breeder operations, turkey and game bird producers, dairy and beef calf rearers and smaller livestock farms. Veterinarians and nutritionists design the anticoccidial programmes and determine product choice and dosing.
North America
In the United States, amprolium products are regulated by the FDA Center for Veterinary Medicine. Use in medicated feeds is governed by 21 CFR 558.55, which covers the 25% Type A medicated article and specifies use levels for broilers, replacement chickens, laying chickens, turkeys, pheasants and calves. Oral dosage forms (9.6% solution and 20% soluble powder) are covered by 21 CFR 520.100, and residue tolerances for cattle, chickens, turkeys, pheasants and eggs are set in 21 CFR 556.50. Amprolium is not on the FDA list of drugs with Veterinary Feed Directive marketing status and is sold over the counter. The approved products include AMPROL 25% (NADA 012-350) and CORID (NADA 013-149). In Canada, the Canadian Food Inspection Agency's Medicating Ingredient Brochure lists amprolium as an over-the-counter medicating ingredient for broilers, replacement chickens, turkeys and calves.
Europe
In the European Union, amprolium is listed in Table 1 of Commission Regulation (EU) No 37/2010 for poultry with no MRL required, for oral use only, based on the CVMP assessment that established an acceptable daily intake of 100 µg/kg body weight. Veterinary medicinal products containing amprolium are authorised nationally or through decentralised and mutual-recognition procedures under Regulation (EU) 2019/6. As a feed additive, amprolium hydrochloride (COXAM) is authorised under Regulation (EC) No 1831/2003 by Commission Implementing Regulation (EU) 2021/2047 for chickens for fattening and chickens reared for laying. In the United Kingdom, products such as Amproline 400 mg/mL are authorised by the Veterinary Medicines Directorate under the Veterinary Medicines Regulations 2013.
Asia Pacific
In China, MARA Announcement No. 194 withdrew growth-promoting drug feed additives from 2020 but retained anticoccidials, which may continue to be used in commercial feed and on farms. Residue limits for veterinary drugs are set by the national standard GB 31650-2019. In Japan, amprolium is used both as a veterinary drug and as a designated feed additive for chickens, and the Ministry of Health, Labour and Welfare sets residue limits for cattle tissues and chicken eggs. In India, the Food Safety and Standards (Contaminants, Toxins and Residues) Second Amendment Regulations, 2018 set a tolerance limit of 0.01 mg/kg for amprolium in edible animal tissues and milk.
Latin America
In Brazil, the Ministry of Agriculture, Livestock and Food Supply regulates feed additives under Normative Instruction No. 13 of 2004, which defines anticoccidials as a category of additive requiring prior registration and a scientifically justified withdrawal period. Normative Instruction No. 1 of 2020 banned tylosin, lincomycin and tiamulin as performance enhancers without restricting registered anticoccidials.
International Standards
No Codex Alimentarius MRL has been established for amprolium, and the substance has not been evaluated by the Joint FAO/WHO Expert Committee on Food Additives. Residue standards are therefore set nationally, which leads to differences between markets that exporters of poultry meat and eggs must manage.
Aug 2022: Bimeda; Acquisition; Acquired Afrivet Southern Africa, including its operations in Zambia and Mozambique, expanding its animal health footprint in Africa.
Nov 2023: Dopharma; Approval; Obtained registration in China for Melovem 30 mg/ml injection for cattle, extending its food-animal portfolio in Asia.
Jan 2024: Huvepharma; Approval; Commission Implementing Regulation (EU) 2024/231 authorised Stenorol (halofuginone) as a coccidiostat feed additive, with Huvepharma NV as holder.
Apr 2024: Phibro Animal Health; Acquisition; Agreed to acquire the Zoetis medicated feed additive portfolio and certain water-soluble products for USD 350 million.
Apr 2024: Virbac; Acquisition; Acquired Sasaeah, a Japanese farm animal vaccine and pharmaceutical company with plants in Japan and Vietnam.
May 2024: Aurora Pharmaceutical; Approval; Received FDA approval for CocciAid (amprolium) for Calves, a generic 9.6% oral solution (ANADA 200-780).
Sep 2024: Huvepharma; Divestiture; Olon S.p.A. acquired Huvepharma Italia.
Oct 2024: Phibro Animal Health; Acquisition; Completed the acquisition of the Zoetis medicated feed additive portfolio, covering more than 37 product lines and six manufacturing sites.
Apr 2025: Interchemie; Investment; Nimbus, together with Maco Investments, acquired a majority stake in Interchemie to support expansion in Asia and Western Europe.
Mar 2026: Huvepharma; Approval; Commission Implementing Regulation (EU) 2026/532 renewed and extended the authorisation of the Coxidin (monensin) coccidiostat feed additive.
Apr 2026: Bimeda; Acquisition; Acquired non-sterile manufacturing assets from Dechra at Pomona, California, to expand US manufacturing capacity.
Jul 2026: Phibro Animal Health; Approval; FDA change of sponsor from Zoetis to Phibro published for anticoccidial combinations, including AMPROL HI-E (amprolium and ethopabate) with BACIFERM.
Jul 2026: Huvepharma; Acquisition; Signed a share purchase agreement to acquire Euroapi Italy S.r.l. and its Brindisi fermentation site, adding about 25% to its fermentation capacity.
Political
Government policies on antimicrobial stewardship in food animals influence the choice between antibiotic and non-antibiotic anticoccidials.
Food security programmes in the Gulf states, Africa and South Asia support investment in domestic poultry production.
Trade policies and sanitary standards for poultry meat affect the residue requirements that producers must meet.
Economic
Growth in incomes and urban populations increases demand for affordable poultry protein.
Feed price volatility affects producer margins and spending on preventive medication.
Generic competition and API pricing determine the price level of amprolium products.
Social
Consumer demand for antibiotic-free and higher-welfare poultry is changing coccidiosis-control programmes.
Cage-free egg commitments increase coccidiosis exposure in layer flocks.
Growing awareness of food safety heightens attention to drug residues in meat and eggs.
Technological
Live coccidiosis vaccines and improved vaccine delivery reduce reliance on in-feed medication.
Improved premix and soluble formulations enhance stability, mixing uniformity and ease of use.
Diagnostic tools for oocyst counting and anticoccidial sensitivity testing support programme design.
Environmental
Intensive housing and litter re-use increase environmental oocyst loads and coccidiosis pressure.
Environmental regulation of chemical API manufacturing in China affects supply continuity.
Climate conditions in tropical regions favour oocyst survival and higher disease pressure.
Legal
Product approvals, feed additive authorisations and withdrawal periods vary by country and define where amprolium can be sold.
Residue tolerances and MRLs differ widely between jurisdictions, with no Codex standard.
Over-the-counter versus prescription status affects the channels through which products reach farms.
Profiles of 33 companies operating in the Amprolium Market market, including revenue, employee count, and market positioning where available.
Showing 33 of 33 companies
Company Headquarters: Carros, Southeastern France, France Founded: 1968 Workforce: ~4825 Company Working: Virbac develops, manufactures, and markets a wide range of veterinary pharmaceutical products and has a market experience of more than fifty years and is one of the top 10 players in the global animal health market. It operates through the livestock and aquaculture business segments, and manufactures products including parasiticides, immunology, antibiotics/dermatology, specialties, equine, and specialized pet food. The company has a presence in more than 100 countries and generates more than 60% of its revenue from outside Europe. It has 11 manufacturing units in different countries and five fully equipped R&D facilities for the development of products.
3 interactive charts drawn from the Amprolium Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Amprolium Market By Physical Form
Global Amprolium Market By Livestock
Global Amprolium Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
